Gaëtan MacGrogan

24.9k total citations · 1 hit paper
159 papers, 6.3k citations indexed

About

Gaëtan MacGrogan is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Gaëtan MacGrogan has authored 159 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 72 papers in Cancer Research and 51 papers in Pathology and Forensic Medicine. Recurrent topics in Gaëtan MacGrogan's work include Breast Cancer Treatment Studies (64 papers), Breast Lesions and Carcinomas (44 papers) and HER2/EGFR in Cancer Research (33 papers). Gaëtan MacGrogan is often cited by papers focused on Breast Cancer Treatment Studies (64 papers), Breast Lesions and Carcinomas (44 papers) and HER2/EGFR in Cancer Research (33 papers). Gaëtan MacGrogan collaborates with scholars based in France, United States and Switzerland. Gaëtan MacGrogan's co-authors include Marc Debled, L. Mauriac, Hervé Bonnefoi, Véronique Brouste, Simone Mathoulin‐Pélissier, M. Durand, Isabelle de Mascarel, David Cameron, F. Bonichon and Richard Iggo and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Gaëtan MacGrogan

150 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of molecular apocrine breast tumours by microarray analysis

2005 585 citations Hervé Bonnefoi, Véronique Becette et al. profile →

Peers

Countries citing papers authored by Gaëtan MacGrogan

Since Specialization

Citations

This map shows the geographic impact of Gaëtan MacGrogan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gaëtan MacGrogan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gaëtan MacGrogan more than expected).

Fields of papers citing papers by Gaëtan MacGrogan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gaëtan MacGrogan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gaëtan MacGrogan. The network helps show where Gaëtan MacGrogan may publish in the future.

Co-authorship network of co-authors of Gaëtan MacGrogan

This figure shows the co-authorship network connecting the top 25 collaborators of Gaëtan MacGrogan. A scholar is included among the top collaborators of Gaëtan MacGrogan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gaëtan MacGrogan. Gaëtan MacGrogan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	65P Multi-site European study of a fully automated artificial intelligence solution for HER2 IHC scoring in breast cancer 2024 ·ESMO Open ·Joanna Cyrta, Vincent Cockenpot, (unknown), (unknown), Rita Canas‐Marques, Gaëtan MacGrogan, (unknown), (unknown), Sabine Declercq, Glenn Broeckx, Frederik Deman, Jeanne Thomassin‐Piana, Marie Brevet, (unknown), (unknown), (unknown), Dror Mevorach, Judith Sandbank, Manuela Vecsler, (unknown)	0
2	An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy 2022 ·ESMO Open ·(unknown), Élodie Darbo, Marc Debled, Véronique Brouste, Valérie Velasco, (unknown), Nicolas Larmonier, (unknown), (unknown), Mónica Arnedos, (unknown), Hervé Bonnefoi, Claire B. Larmonier, Gaëtan MacGrogan	8
3	Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations 2021 ·Modern Pathology ·(unknown), Gaëtan MacGrogan, Aurélie Bertaut, Sylvain Ladoire, Patrick Arveux, Isabelle Desmoulins, Hervé Bonnefoi, Catherine Loustalot, (unknown), Françoise Beltjens, (unknown), Céline Charon‐Barra, Corentin Richard, Romain Boidot, Laurent Arnould	23
4	159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers 2021 ·Annals of Oncology ·Jacqueline Lehmann‐Che, (unknown), Ludovic Lacroix, Magali Lacroix‐Triki, Laurent Arnould, Pierre‐Jean Lamy, Véronique Quillien, Florence Godey, Isabelle Soubeyran, Gaëtan MacGrogan, Juliette Haudebourg, (unknown), Marie‐Françoise Heymann, (unknown), (unknown), (unknown), (unknown), Linda Dainese, L. Karayan-Tapon, Frédérique Penault‐Llorca	0
5	Machine Learning and Mechanistic Modeling for Prediction of Metastatic Relapse in Early-Stage Breast Cancer 2020 ·JCO Clinical Cancer Informatics ·Chiara Nicolò, C. Périer, Mélanie Prague, Carine Bellera, Gaëtan MacGrogan, Olivier Saut, Sébastien Benzekry	45
6	The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas 2019 ·Clinical Cancer Research ·Sabrina Croce, Tom Lesluyes, Carine Valle, Loubna Mhamdi, (unknown), Gaëlle Pérot, Eberhard Stoeckle, Jean‐Christophe Noël, (unknown), Mojgan Devouassoux‐Shisheboran, Denis Querleu, Frédéric Guyon, Anne Floquet, Camille Chakiba, Laétitia Mayeur, (unknown), Gaëtan MacGrogan, Isabelle Soubeyran, Sophie Le Guellec, Frédéric Chibon	15
7	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes 2019 ·British Journal of Cancer ·(unknown), Hervé Bonnefoi, Gaëtan MacGrogan, Coralie Poncet, Richard Iggo, Fanny Pommeret, Thomas Grellety, Denis Larsimont, Véronique Becette, Olivier Kerdraon, Frédéric Bibeau, Jean‐Pierre Ghnassia, Jean‐Michel Picquenot, Jeremy Thomas, Jean‐Christophe Tille, Leen Slaets, Alexandre Bodmer, Jonas Bergh, David Cameron	13
8	Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target 2018 ·Clinical Cancer Research ·Thomas Grellety, Céline Callens, Élodie Richard, Adrien Briaux, Valérie Velasco, Marina Pulido, Anthony Gonçalvès, Pierre Gestraud, Gaëtan MacGrogan, Hervé Bonnefoi, Bruno Cardinaud	19
9	The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours 2016 ·The Journal of Pathology ·Élodie Richard, Thomas Grellety, Valérie Velasco, Gaëtan MacGrogan, Hervé Bonnefoi, Richard Iggo	28
10	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer 2013 ·Cancer Research ·Marine Malleter, Sébastien Tauzin, Alban Bessede, Rémy Castellano, Armelle Goubard, Florence Godey, Jean Lévêque, Pascal Jézéquel, L. Campion, Mario Campone, Thomas Ducret, Gaëtan MacGrogan, Laure Debure, Yves Collette, Pierre Vacher, Patrick Legembre	69
11	Imaging features of sporadic breast cancer in women under 40 years old: 97 cases 2013 ·European Radiology ·(unknown), Gaëtan MacGrogan, Hervé Bonnefoi, (unknown), (unknown), Véronique Brouste, M. Boisserie-Lacroix	34
12	Instant‐quality fluorescence in‐situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study 2013 ·Histopathology ·Camille Franchet, Thomas Filleron, Anne Cayre, (unknown), Frédérique Penault‐Llorca, Jocelyne Jacquemier, Gaëtan MacGrogan, Laurent Arnould, Magali Lacroix‐Triki	9
13	Is it useful to detect lymphovascular invasion in lymph node‐positive patients with primary operable breast cancer? 2010 ·Cancer ·(unknown), Marc Debled, Gaëtan MacGrogan, Véronique Brouste, (unknown), Isabelle Soubeyran, C. Tunon de Lara, L. Mauriac, Isabelle de Mascarel	29
14	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole 2008 ·Journal of Clinical Oncology ·(unknown), Anita Giobbie‐Hurder, MM Regan, (unknown), (unknown), Patrizia Dell’Orto, Eugenio Maiorano, Gaëtan MacGrogan, Stephen Braye, (unknown), Patrick Neven, Zsolt Orosz, (unknown), Fiona Knox, B. Thürlimann, K.N. Price, Monica Castiglione‐Gertsch, RD Gelber, B A Gusterson, Aron Goldhirsch	3
15	Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. 2007 ·PubMed ·M. Tubiana-Hulin, Véronique Becette, Ivan Bièche, L. Mauriac, Gilles Romieu, Frédéric Bibeau, Gaëtan MacGrogan, Hugues Bourgeois, P. Chollet, Rémy Defrance, Frédérique Spyratos	17
16	Prise en charge des atypies épithéliales du sein 2007 ·Annales de Pathologie ·Isabelle de Mascarel, Gaëtan MacGrogan	9
17	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity 2007 ·Breast Cancer Research ·Anne Vincent‐Salomon, Nadège Gruel, Carlo Lucchesi, Gaëtan MacGrogan, R. Dendale, Brigitte Sigal‐Zafrani, Michel Longy, Virginie Raynal, Gaëlle Pierron, Isabelle de Mascarel, (unknown), Dominique Stoppa‐Lyonnet, Jean‐Yves Pierga, Rémy Salmon, Xavier Sastre‐Garau, Alain Fourquet, Olivier Delattre, Patricia de Crémoux, Alain Aurias	133
18	Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* Study 2003 ·Histopathology ·Anne Vincent‐Salomon, Gaëtan MacGrogan, J Couturier, Laurent Arnould, Yves Denoux, Maryse Fiche, J Jacquemier, (unknown), Frédérique Penault‐Llorca, C Rigaud, Pascal Roger, Isabelle Treilleux, (unknown), Simone Mathoulin‐Pélissier, V Le Doussal	83
19	Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer 2003 ·British Journal of Cancer ·Laurent Arnould, Yves Denoux, Gaëtan MacGrogan, Frédérique Penault–Llorca, Maryse Fiche, Isabelle Treilleux, M.C. Mathieu, Anne Vincent‐Salomon, M O Vilain, J Couturier	93
20	Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women 2002 ·Annals of Oncology ·L. Mauriac, Marc Debled, M. Durand, Anne Floquet, (unknown), Corinne Dagada, Nathalie Trufflandier, Gaëtan MacGrogan	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact